PRODUCT LITERATURE

Remdesivir: First Approval

---

The antiviral agent remdesivir (Veklury®; Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity
against viruses from several families. Having demonstrated potent antiviral activity against coronaviruses in preclinical studies, remdesivir emerged as a candidate drug for the treatment of the novel coronavirus disease 2019 (COVID19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, during the current global
pandemic. Phase III evaluation of remdesivir in the treatment of COVID-19 commenced in early 2020 and has thus
far yielded promising results. In late May 2020, Taiwan conditionally approved the use of remdesivir in patients with
severe COVID-19.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Jubi-R

Specific Detail Info

-

Statement of Responsibility

Drugs. 2020 Sep 1 : 1–9

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment